Klaviyo, Inc. has recently disclosed a major stock sale involving over 2.7 million shares of its Series A common stock. This sale, executed by Summit Partners Growth Equity Fund IX-A, L.P., is valued at approximately $57 million. The transaction is significant as it reflects ongoing shifts in ownership within the company, especially in the wake of its recent IPO.
Founded in Boston, Klaviyo operates in the prepackaged software industry, specifically classified under SIC 7372. The company has been making strides in the marketing automation sector, providing businesses with tools to enhance customer engagement and drive sales.
The SEC filing, dated November 9, 2026, indicates that Summit Partners sold 2,742,281 shares. The shares were acquired through pre-IPO transactions, with an acquisition date of September 20, 2023. The filing noted that the sale took place on the same date as the filing, November 9, 2026.
According to the filing, the aggregate market value of the shares sold was approximately $57,094,290.42, with the total outstanding shares of Klaviyo reported at 130,150,680. The filing also mentioned that the shares were sold through Barclays Capital Inc., a well-known broker.
This stock sale could have implications for Klaviyo's market positioning and investor sentiment. As a large accelerated filer, Klaviyo is subject to rigorous reporting requirements, and such transactions are closely monitored by investors and analysts alike.
Summit Partners Growth Equity Fund IX-A, L.P. has been a significant stakeholder in Klaviyo, and this sale may indicate a strategic decision to realize gains or reallocate investments. The broader implications for the prepackaged software industry could involve shifts in investor confidence and market dynamics as competitors observe these developments.
Looking ahead, it remains to be seen how this transaction will impact Klaviyo's stock performance and investor relations. The filing does not specify any upcoming events or additional filings related to this sale, leaving stakeholders to speculate on the next steps.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










